Hims & Hers Falls 11% After FDA Announces Shortage Has Ended for Eli Lilly Drugs
Hims & Hers Falls 11% After FDA Announces Shortage Has Ended for Eli Lilly Drugs
Hims & Hers 股價下跌11%，FDA宣佈Eli Lilly藥物短缺已結束
$Hims & Hers Health (HIMS.US)$ dropped 11% after the Food and Drug Administration announced shortages of Eli Lilly's obesity and diabetes drugs Zepbound and Mounjaro have ended.
$Hims & Hers Health (HIMS.US)$ 在美國食品藥品監督管理局宣佈Eli Lilly的肥胖和糖尿病藥物Zepbound和Mounjaro的短缺問題已經解決後，其股價下跌了11%。
The company sells direct-to-consumer generic prescription medicines, including weight-loss drugs, and with Lilly's shortages, had taken advantage by creating copycat treatments.
該公司銷售直接面向消費者的通用處方藥，包括減肥藥，在Eli Lilly藥物短缺的情況下，通過開發仿製藥獲利。
Investors will keep their eyes on the upcoming Hims & Hers Health earnings report. Prior to Thursday's news, shares had increased 33.17% in the last month.
投資者將繼續關注即將發佈的Hims & Hers Health收益報告。在週四的消息之前，股價在過去一個月已上漲33.17%。
資訊熱榜
更新時間